From less tolerance for failure as pressure mounts on pipelines to ongoing consequences of regulatory changes, such as the introduction of US Inflation Reduction Act, life sciences companies will face a number of challenges in the coming year. Precisely how health care systems deliver novel medicines is also high on the list of concerns.
Industry experts from across the wider Norstella business shared their predictions going into 2024.